VOLTAREN SUPPOSITORY

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

DICLOFENAC SODIUM

Disponibbli minn:

NOVARTIS PHARMACEUTICALS CANADA INC

Kodiċi ATC:

M01AB05

INN (Isem Internazzjonali):

DICLOFENAC

Dożaġġ:

100MG

Għamla farmaċewtika:

SUPPOSITORY

Kompożizzjoni:

DICLOFENAC SODIUM 100MG

Rotta amministrattiva:

RECTAL

Unitajiet fil-pakkett:

30

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0114417001; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2021-11-08

Karatteristiċi tal-prodott

Page 1 of 43
PRODUCT MONOGRAPH
PR
VOLTAREN
®
PR
VOLTAREN
® SR
(diclofenac sodium)
50 mg Enteric-Coated Tablets
75 and 100 mg Slow-Release Tablets
50 and 100 mg Suppositories
Acetic Acid Derivatives and Related Substances
Novartis Pharmaceuticals Canada Inc.
Date of Preparation:
385 Bouchard Blvd.,
July 5, 1989
Dorval, Quebec H9S 1A9
Date of Revision:
October 20, 2021
Control no. 253534
VOLTAREN and VOLTAREN SR are registered trademarks.
Page 2 of 43
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................
3
CONTRAINDICATIONS
....................................................................................................
4
WARNINGS AND PRECAUTIONS
...................................................................................
5
ADVERSE REACTIONS
...................................................................................................16
DRUG
INTERACTIONS....................................................................................................20
DOSAGE AND
ADMINISTRATION.................................................................................23
OVERDOSAGE
.................................................................................................................25
ACTION AND CLINICAL PHARMACOLOGY
................................................................26
STORAGE AND
STABILITY............................................................................................28
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................28
PART II: SCIENTIFIC INFORMATION
...........................................................................29
PHARMACEUTICAL
INFORMATION.............................................................................29
CLINICAL TRIALS
.............